Applying New Stem Cell Science to Reboot the Immune System

Magenta Therapeutics (NASDAQ: MGTA) is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients.

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

August 9, 2018
Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results

August 8, 2018
Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference

June 20, 2018
Magenta Therapeutics Announces Pricing of Initial Public Offering

Read More News

Associated Team Members

Alexis Borisy

Stephen Sherwin, M.D.
Venture Partner